Ocular pharmacokinetics of bimatoprost formulated in DuraSite compared to bimatoprost 0.03% ophthalmic solution in pigmented rabbit eyes

Ocular pharmacokinetics of bimatoprost formulated in DuraSite compared to bimatoprost 0.03% ophthalmic solution in pigmented rabbit eyes

Afshin Shafiee,1 Lyle M Bowman,2 Eddie Hou,2 Kamran Hosseini1,3 1Preclinical, 2Development, 3Clinical, InSite Vision, Alameda, CA, USA Purpose: To compare the aqueous humor (AH) and iris-ciliary body (ICB) concentration of bimatoprost in rabbit eyes treated with ISV-215 (0.03% bimatoprost formulated...

Full description

Bibliographic Details
Main Authors:	Shafiee A, Bowman LM, Hou E, Hosseini K
Format:	Article
Language:	English
Published:	Dove Medical Press 2013-07-01
Series:	Clinical Ophthalmology
Online Access:	http://www.dovepress.com/ocular-pharmacokinetics-of-bimatoprost-formulated-in-durasite-compared-a13865

Similar Items

Impact of topical bimatoprost 0.01% and bimatoprost 0.03% on conjunctival irritation in rabbits
by: Abayomi B Ogundele, et al.
Published: (2010-02-01)

Aqueous humor penetration of topical bimatoprost 0.01% and bimatoprost 0.03% in rabbits: response to authors
by: Chang-Lin J-E, et al.
Published: (2011-08-01)

The Effect of Topical Bimatoprost 0.03% Solution on Androgenic Alopecia
by: Dwi Aryaningrum, et al.
Published: (2018-11-01)

Bimatoprost ophthalmic solution 0.03% lowered intraocular pressure of normal-tension glaucoma with minimal adverse events
by: Tsumura T, et al.
Published: (2012-09-01)

Bimatoprost ophthalmic solution 0.03% lowered intraocularpressure of normal-tension glaucoma with minimal adverse events [Corrigendum]
by: Tsumura T, et al.
Published: (2013-07-01)

Ocular pharmacokinetics and tolerability of bimatoprost ophthalmic solutions administered once or twice daily in rabbits, and clinical dosing implications
by: Shen J, et al.
Published: (2017-09-01)

Bimatoprost ophthalmic solution 0.03% lowered intraocular pressure of normal-tension glaucoma with minimal adverse events. [Corrigendum]
by: Tsumura T, et al.
Published: (2013-01-01)

Patient considerations in ocular hypertension: role of bimatoprost ophthalmic solution
by: Lee D, et al.
Published: (2017-07-01)

Ocular pharmacokinetics and tolerability of bimatoprost ophthalmic solutions administered once or twice daily in rabbits, and clinical dosing implications [Corrigendum]
by: Shen J, et al.
Published: (2018-08-01)

Preservative-free bimatoprost 0.03% in patients with primary open-angle glaucoma or ocular hypertension in clinical practice
by: Pillunat LE, et al.
Published: (2016-09-01)

The efficiency of monotherapy of patients with primary open-angle glaucoma with Bimatoprost 0.03 % (Bimoptic)
by: S. A. Korotkikh, et al.
Published: (2018-12-01)

Effects of treatment with bimatoprost 0.03% for 3 years in patients with normal-tension glaucoma
by: Inoue K, et al.
Published: (2014-06-01)

In vivo comparative study of ocular vasodilation, a relative indicator of hyperemia, in guinea pigs following treatment with bimatoprost ophthalmic solutions 0.01% and 0.03%
by: Abayomi B Ogundele, et al.
Published: (2010-06-01)

Managing refractory glaucoma with a fixed combination of bimatoprost (0.03%) and timolol (0.5%)
by: Moataz E Gheith, et al.
Published: (2008-03-01)

Evaluating intraocular pressure-lowering solutions for the treatment of open-angle glaucoma: comparison between bimatoprost 0.03% and bimatoprost 0.01% – an observational switch study
by: Deshpande SS, et al.
Published: (2017-07-01)

Floppy eyelid syndrome and ectropion improvement after 1 month of 0.03% Bimatoprost topical therapy
by: Alessandra De Gregorio, et al.
Published: (2020-12-01)

Comparative study of the stability of bimatoprost 0.03% and latanoprost 0.005%: A patient-use study
by: Umbelino Cristiano C, et al.
Published: (2008-06-01)

Bimatoprost 0.01% or 0.03% in patients with glaucoma or ocular hypertension previously treated with latanoprost: two randomized 12-week trials
by: Myers JS, et al.
Published: (2014-03-01)

Bimatoprost in dermatology
by: Abhijeet K Jha, et al.
Published: (2018-01-01)

Evaluation of palpebral fissure and orbital volume after bimatoprost 0.03% orbital injections. Experimental study in rats
by: Nilson Lopes da Fonseca Junior, et al.
Published: (2014-12-01)

Preservative-free bimatoprost 0.03%/timolol 0.5% fixed combination in patients with glaucoma in clinical practice
by: Pfennigsdorf S, et al.
Published: (2016-09-01)

Long-term safety evaluation of bimatoprost ophthalmic solution 0.03%: a pooled analysis of six double-masked, randomized, active-controlled clinical trials
by: Wirta D, et al.
Published: (2011-06-01)

Efficacy and safety of fixed-combination bimatoprost/timolol ophthalmic solution
by: Moon SB, et al.
Published: (2017-06-01)

Bimatoprost in the treatment of eyelash hypotrichosis
by: Simon K Law
Published: (2010-04-01)

Azithromycin in DuraSite&reg; for the treatment of blepharitis
by: Jodi Luchs
Published: (2010-06-01)

Role of prostaglandins and specific place in therapy of bimatoprost in the treatment of elevated intraocular pressure and ocular hypertension: A closer look at the agonist properties of bimatoprost and the prostamides
by: Scott D Smid
Published: (2009-11-01)

Efficacy and safety of bimatoprost in glaucoma and ocular hypertension in non-responder patients
by: Nicholas Brennan, et al.
Published: (2017-08-01)

Management of hypotrichosis of the eyelashes: Focus on bimatoprost
by: Steven Fagien
Published: (2010-04-01)

Efficacy of bimatoprost 0.03% in reducing intraocular pressure in patients with 360° synechial angle-closure glaucoma: A preliminary study
by: Vyas Prateep, et al.
Published: (2011-01-01)

A pharmacoeconomic analysis to determine the relative cost-effectiveness of bimatoprost 0.03% eye drops and brimonidine 0.2% eye drops in patients of primary open-angle glaucoma/ocular hypertension
by: Navreet Kaur Natt, et al.
Published: (2014-01-01)

Iris and periocular adverse reactions to bimatoprost in Japanese patients with glaucoma or ocular hypertension
by: Inoue K, et al.
Published: (2012-01-01)

Effects of Latanoprost and Bimatoprost on the Expression of Molecules Relevant to Ocular Inflow and Outflow Pathways.
by: Xiaohong Li, et al.
Published: (2016-01-01)

Corneal alterations induced by topical application of commercial latanoprost, travoprost and bimatoprost in rabbit.
by: Wensheng Chen, et al.
Published: (2014-01-01)

Safety data on in situ gelling bimatoprost loaded nanovesicular formulations
by: Monika Yadav, et al.
Published: (2019-08-01)

Tear biomarkers in latanoprost and bimatoprost treated eyes.
by: Shweta Reddy, et al.
Published: (2018-01-01)

Therapeutic potential of bimatoprost for the treatment of eyebrow hypotrichosis
by: Chanasumon N, et al.
Published: (2018-02-01)

Bimatoprost Effects on Aqueous Humor Dynamics in Monkeys
by: David F. Woodward, et al.
Published: (2010-01-01)

Efficacy and safety of fixed-combination travoprost 0.004%/timolol 0.5% in patients transitioning from bimatoprost 0.03%/timolol 0.5% combination therapy
by: Schnober D, et al.
Published: (2015-05-01)

Correction: Corneal Alterations Induced by Topical Application of Commercial Latanoprost, Travoprost and Bimatoprost in Rabbit
by: The Staff
Published: (2014-01-01)

Analysis of Bimatoprost-Induced changes on Rabbits eyelash Follicle: Clinical and Electron microscopic study
by: Sayed KM, et al.
Published: (2019-12-01)